Committed change of real-time quantitative PCR to droplet digital PCR for monitoring BCR :: ABL1 transcripts in tyrosine kinase inhibitor treated CML

Abstract excerpt

Objectives We performed a feasibility study of an FDA-approved commercial ddPCR assay to measure BCR::ABL1 in CML patients treated using TKI therapy.Methods Assay performance of standard RQ-PCR and commercially available FDA-approved ddPCR were compared to measure BCR::ABL1 p210 transcripts in RNA samples from 100 CML patients who received TKI therapy.Results %BCR::ABL1/ABL1IS levels obtained from both methods...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Chronic Lymphocytic Leukemia Research
• Share to Chronic Myeloid Leukemia Treatments
• Share to Lymphoma Diagnosis and Treatment